EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

Daniela Kocher, Lei Cao, Romain Guiho, Melanie Langhammer, Yun-Lu Lai, Pauline Becker, Hiba Hamdi, Dennis Friedel, Florian Selt, David Vonhören, Julia Zaman, Gintvile Valinciute und 17 weitere

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04672-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Daniela Kocher und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Microglia, Glioma, Cytokines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, rapid tumor regrowth, also referred to as rebound growth, may occur once treatment is stopped, constituting a significant clinical challenge.

Methods

Four patient-derived pediatric glioma models were investigated to model rebound growth in vitro based on viable cell counts in response to MAPKi treatment and withdrawal. A multi-omics dataset (RNA sequencing and LC-MS/MS based phospho-/proteomics) was generated to investigate possible rebound-driving mechanisms. Following in vitro validation, putative rebound-driving mechanisms were validated in vivo using the BT-40 orthotopic xenograft model.

Results

Of the tested models, only a BRAF V600E -driven model (BT-40, with additional CDKN2A/B del) showed rebound growth upon MAPKi withdrawal. Using this model, we identified a rapid reactivation of the MAPK pathway upon MAPKi withdrawal in vitro, also confirmed in vivo. Furthermore, transient overactivation of key MAPK molecules at transcriptional (e.g. FOS ) and phosphorylation (e.g. pMEK) levels, was observed in vitro. Additionally, we detected increased expression and secretion of cytokines (CCL2, CX3CL1, CXCL10 and CCL7) upon MAPKi treatment, maintained during early withdrawal. While increased cytokine expression did not have tumor cell intrinsic effects, presence of these cytokines in conditioned media led to increased attraction of microglia cells in vitro.

Conclusion

Taken together, these data indicate rapid MAPK reactivation upon MAPKi withdrawal as a tumor cell intrinsic rebound-driving mechanism. Furthermore, increased secretion of microglia-recruiting cytokines may play a role in treatment response and rebound growth upon withdrawal, warranting further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafMicrogliaGliomaCytokinesBrain NeoplasmsMutationProtein Kinase InhibitorsHumansAnimalsXenograft Model Antitumor AssaysChildMiceCell ProliferationCell Line, TumorMAP Kinase Signaling System

Stichwörter der Autor:innen

CytokinesMAPK inhibitorPediatric low-grade gliomaRebound growthTreatment withdrawalTumor microenvironment

Substanzen

Proto-Oncogene Proteins B-rafCytokinesBRAF protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
  • German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit Pediatric Oncology, Heidelberg, Germany.
  • Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Developmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, WC1N 1EH, London, UK.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Förderung

  • Universitätsklinikum Heidelberg

Zitieren

APA

Kocher, D., Cao, L., Guiho, R., Langhammer, M., Lai, Y. L., Becker, P., Hamdi, H., Friedel, D., Selt, F., Vonhören, D., Zaman, J., Valinciute, G., Herter, S., Picard, D., Rettenmeier, J., Maass, K. K., Pajtler, K. W., Remke, M., von Deimling, A., …, & Sigaud, R. (2024). Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04672-9

Vancouver

Kocher D, Cao L, Guiho R, Langhammer M, Lai YL, Becker P, et al. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04672-9

BibTeX
@article{Kocher2024,
  author = {Kocher, Daniela and Cao, Lei and Guiho, Romain and Langhammer, Melanie and Lai, Yun-Lu and Becker, Pauline and Hamdi, Hiba and Friedel, Dennis and Selt, Florian and Vonhören, David and Zaman, Julia and Valinciute, Gintvile and Herter, Sonja and Picard, Daniel and Rettenmeier, Johanna and Maass, Kendra K and Pajtler, Kristian W and Remke, Marc and von Deimling, Andreas and Pusch, Stefan and Pfister, Stefan M and Oehme, Ina and Jones, David T W and Halbach, Sebastian and Brummer, Tilman and Martinez-Barbera, Juan Pedro and Witt, Olaf and Milde, Till and Sigaud, Romain},
  title = {Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04672-9}
}
Kostenlos starten →